An introduction to the endogenous cannabinoid system

Biological Psychiatry

Volumn 79, Issue 7, 2016, Pages 516-525

  Lu, Hui Chen ^a   MacKie, Ken ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Cannabinoid; Cannabis; Lipid signaling; Retrograde messenger; Schizophrenia; Synaptic plasticity

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID RECEPTOR; CANNABIS; ENDOCANNABINOID; INWARDLY RECTIFYING POTASSIUM CHANNEL; TETRAHYDROCANNABINOL; TRANSIENT RECEPTOR POTENTIAL CHANNEL; ACYLGLYCEROL; AMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; DRONABINOL; GLYCERYL 2-ARACHIDONATE;

BIOLOGICAL ACTIVITY; CHEMICAL STRUCTURE; HUMAN; LONG TERM DEPRESSION; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ARACHIDONIC ACIDS; CANNABINOID RECEPTOR AGONISTS; DRONABINOL; ENDOCANNABINOIDS; GLYCERIDES; HUMANS; NEURONAL PLASTICITY; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SCHIZOPHRENIA;

EID: 84949845531     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2015.07.028     Document Type: Review

References (133)

1. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW (2000): Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: Antagonism by anandamide. Mol Pharmacol 57:1045-1050.
2. Luk T, Jin W, Zvonok A, Lu D, Lin XZ, Chavkin C, et al. (2004): Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. Br J Pharmacol 142: 495-500.
3. Mackie K, Devane WA, Hille B (1993): Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol 44:498-503.
4. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. (2002): International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
5. Bae JS, Kim JY, Park BL, Kim JH, Kim B, Park CS, et al. (2014): Genetic association analysis of CNR1 and CNR2 polymorphisms with schizophrenia in a Korean population. Psychiatr Genet 24: 225-229.
6. Seifert J, Ossege S, Emrich HM, Schneider U, Stuhrmann M (2007): No association of CNR1 gene variations with susceptibility to schizophrenia. Neurosci Lett 426:29-33.
7. Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M, et al. (2002): CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 7: 515-518.
8. Norrod AG, Puffenbarger RA (2007): Genetic polymorphisms of the endocannabinoid system. Chem Biodivers 4:1926-1932.
9. Hamdani N, Tabeze JP, Ramoz N, Ades J, Hamon M, Sarfati Y, et al. (2008): The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia. Eur Neuropsychopharmacol 18:34-40.
10. Mackie K (2005): Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 168:299-325.
11. Nyiri G, Cserep C, Szabadits E, Mackie K, Freund TF (2005): CB1 cannabinoid receptors are enriched in the perisynaptic annulus and on preterminal segments of hippocampal GABAergic axons. Neuroscience 136:811-822.
12. Tsou K, Mackie K, Sanudo-Pena MC, Walker JM (1999): Cannabinoid CB1 receptors are localized primarily on cholecystokinincontaining GABAergic interneurons in the rat hippocampal formation. Neuroscience 93:969-975.
13. Bodor AL, Katona I, Nyiri G, Mackie K, Ledent C, Hajos N, et al. (2005): Endocannabinoid signaling in rat somatosensory cortex: Laminar differences and involvement of specific interneuron types. J Neurosci 25:6845-6856.
14. Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, et al. (1999): Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19:4544-4558.
15. Marsicano G, Lutz B (1999): Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11:4213-4225.
16. Matyas F, Yanovsky Y, Mackie K, Kelsch W, Misgeld U, Freund TF (2006): Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 137:337-361.
17. Uchigashima M, Narushima M, Fukaya M, Katona I, Kano M, Watanabe M (2007): Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci 27:3663-3676.
18. Matyas F, Watanabe M, Mackie K, Katona I, Freund TF (2007): Molecular architecture of the cannabinoid signaling system in the core of the nucleus accumbens. Ideggyogy Sz 60:187-191.
19. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998): Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393-411.
20. Suarez J, Bermudez-Silva FJ, Mackie K, Ledent C, Zimmer A, Cravatt BF, et al. (2008): Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol 509:400-421.
21. Safo PK, Cravatt BF, Regehr WG (2006): Retrograde endocannabinoid signaling in the cerebellar cortex. Cerebellum 5:134-145.
22. Rodriguez JJ, Mackie K, Pickel VM (2001): Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci 21:823-833.
23. Han J, Kesner P, Metna-Laurent M, Duan T, Xu L, Georges F, et al. (2012): Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 148:1039-1050.
24. Molina-Holgado E, Vela JM, Arevalo-Martin A, Almazan G, Molina- Holgado F, Borrell J, et al. (2002): Cannabinoids promote oligodendrocyte progenitor survival: Involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 22: 9742-9753.
25. Ramirez SH, Hasko J, Skuba A, Fan S, Dykstra H, McCormick R, et al. (2012): Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J Neurosci 32:4004-4016.
26. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, et al. (2003): Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23:1398-1405.
27. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. (2005): Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310:329-332.
28. Viscomi MT, Oddi S, Latini L, Pasquariello N, Florenzano F, Bernardi G, et al. (2009): Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci 29:4564-4570.
29. Atwood BK, Mackie K (2010): CB2: A cannabinoid receptor with an identity crisis. Br J Pharmacol 160:467-479.
30. Ishiguro H, Horiuchi Y, Ishikawa M, Koga M, Imai K, Suzuki Y, et al. (2010): Brain cannabinoid CB2 receptor in schizophrenia. Biol Psychiatry 67:974-982.
31. Khella R, Short JL, Malone DT (2014): CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice. Psychopharmacology (Berl) 231:3071-3087.
32. Ortega-Alvaro A, Aracil-Fernandez A, Garcia-Gutierrez MS, Navarrete F, Manzanares J (2011): Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice. Neuropsychopharmacology 36:1489-1504.
33. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN (2005): Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95:437-445.
34. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, et al. (1999): Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452-457.
35. Bouaboula M, Hilairet S, Marchand J, Fajas L, Le Fur G, Casellas P (2005): Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol 517: 174-181.
36. O'Sullivan SE (2007): Cannabinoids go nuclear: Evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152:576-582.
37. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez De Fonseca F, et al. (2003): Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425:90-93.
38. Luchicchi A, Lecca S, Carta S, Pillolla G, Muntoni AL, Yasar S, et al. (2010): Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: Involvement of PPAR-alpha nuclear receptors. Addict Biol 15:277-288.
39. Pacher P, Batkai S, Kunos G (2006): The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389-462.
40. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, et al. (2011): Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334: 809-813.
41. Caille S, Alvarez-Jaimes L, Polis I, Stouffer DG, Parsons LH (2007): Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine selfadministration. J Neurosci 27:3695-3702.
42. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999): Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10:1665-1669.
43. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, et al. (2004): Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29:2108-2114.
44. Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S, et al. (2009): Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry 194: 371-372.
45. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D (1999): Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358-363.
46. Schmid PC, Reddy PV, Natarajan V, Schmid HH (1983): Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type. J Biol Chem 258: 9302-9306.
47. Liu J, Wang L, Harvey-White J, Osei-Hyiaman D, Razdan R, Gong Q, et al. (2006): A biosynthetic pathway for anandamide. Proc Natl Acad Sci U S A 103:13345-13350.
48. Simon GM, Cravatt BF (2010): Characterization of mice lacking candidate N-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo. Mol Biosyst 6:1411-1418.
49. Tsuboi K, Ikematsu N, Uyama T, Deutsch DG, Tokumura A, Ueda N (2013): Biosynthetic pathways of bioactive N-acylethanolamines in brain. CNS Neurol Disord Drug Targets 12:7-16.
50. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, et al. (1994): Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686-691.
51. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (2004): Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279:5298-5305.
52. Leung D, Saghatelian A, Simon GM, Cravatt BF (2006): Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45:4720-4726.
53. Tsuboi K, Okamoto Y, Ikematsu N, Inoue M, Shimizu Y, Uyama T, et al. (2011): Enzymatic formation of N-acylethanolamines from N-acylethanolamine plasmalogen through N-acylphosphatidylethanolamine- hydrolyzing phospholipase D-dependent and -independent pathways. Biochim Biophys Acta 1811:565-577.
54. Shonesy BC, Winder DG, Patel S, Colbran RJ (2015): The initiation of synaptic 2-AG mobilization requires both an increased supply of diacylglycerol precursor and increased postsynaptic calcium. Neuropharmacology 91:57-62.
55. Jung KM, Astarita G, Zhu C, Wallace M, Mackie K, Piomelli D (2007): A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization. Mol Pharmacol 72:612-621.
56. Murataeva N, Straiker A, Mackie K (2014): Parsing the players: 2- Arachidonoylglycerol synthesis and degradation in the CNS. Br J Pharmacol 171:1379-1391.
57. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, et al. (2003): Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163:463-468.
58. Tanimura A, Yamazaki M, Hashimotodani Y, Uchigashima M, Kawata S, Abe M, et al. (2010): The endocannabinoid 2- arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron 65: 320-327.
59. Gao Y, Vasilyev DV, Goncalves MB, Howell FV, Hobbs C, Reisenberg M, et al. (2010): Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci 30:2017-2024.
60. Katona I, Urban GM, Wallace M, Ledent C, Jung KM, Piomelli D, et al. (2006): Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci 26:5628-5637.
61. Yoshida T, Fukaya M, Uchigashima M, Miura E, Kamiya H, Kano M, et al. (2006): Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. J Neurosci 26:4740-4751.
62. Romano C, Sesma MA, McDonald CT, O'Malley K, Van den Pol AN, Olney JW (1995): Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol 355:455-469.
63. Jain T, Wager-Miller J, Mackie K, Straiker A (2013): Diacylglycerol lipasealpha (DAGLalpha) and DAGLbeta cooperatively regulate the production of 2-arachidonoyl glycerol in autaptic hippocampal neurons. Mol Pharmacol 84:296-302.
64. Hsu KL, Tsuboi K, Adibekian A, Pugh H, Masuda K, Cravatt BF (2012): DAGLbeta inhibition perturbs a lipid network involved in macrophage inflammatory responses. Nat Chem Biol 8:999-1007.
65. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996): Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83-87.
66. Woodward DF, Liang Y, Krauss AH (2008): Prostamides (prostaglandin- ethanolamides) and their pharmacology. Br J Pharmacol 153:410-419.
67. Urquhart P, Nicolaou A, Woodward DF (2015): Endocannabinoids and their oxygenation by cyclo-oxygenases, lipoxygenases and other oxygenases. Biochim Biophys Acta 1851:366-376.
68. Hermanson DJ, Hartley ND, Gamble-George J, Brown N, Shonesy BC, Kingsley PJ, et al. (2013): Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. Nat Neurosci 16:1291-1298.
69. Hermanson DJ, Gamble-George JC, Marnett LJ, Patel S (2014): Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation. Trends Pharmacol Sci 35: 358-367.
70. Tsuboi K, Sun YX, Okamoto Y, Araki N, Tonai T, Ueda N (2005): Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem 280:11082-11092.
71. Blankman JL, Simon GM, Cravatt BF (2007): A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2- arachidonoylglycerol. Chem Biol 14:1347-1356.
72. Ludanyi A, Hu SS, Yamazaki M, Tanimura A, Piomelli D, Watanabe M, et al. (2011): Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2- arachidonoylglycerol in the human hippocampus. Neuroscience 174: 50-63.
73. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, et al. (2010): Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13:1113-1119.
74. Ignatowska-Jankowska BM, Ghosh S, Crowe MS, Kinsey SG, Niphakis MJ, Abdullah RA, et al. (2014): In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: Antinociceptive activity without cannabimimetic side effects. Br J Pharmacol 171:1392-1407.
75. Kinsey SG, Wise LE, Ramesh D, Abdullah R, Selley DE, Cravatt BF, et al. (2013): Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1- mediated antinociceptive and gastroprotective effects. J Pharmacol Exp Ther 345:492-501.
76. Kinsey SG, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH (2011): Inhibition of endocannabinoid catabolic enzymes elicits anxiolyticlike effects in the marble burying assay. Pharmacol Biochem Behav 98:21-27.
77. Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J, et al. (2010): The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci 13: 951-957.
78. Naydenov AV, Horne EA, Cheah CS, Swinney K, Hsu KL, Cao JK, et al. (2014): ABHD6 blockade exerts antiepileptic activity in PTZinduced seizures and in spontaneous seizures in R6/2 mice. Neuron 83:361-371.
79. Thomas G, Betters JL, Lord CC, Brown AL, Marshall S, Ferguson D, et al. (2013): The serine hydrolase ABHD6 is a critical regulator of the metabolic syndrome. Cell Rep 5:508-520.
80. Oparina NY, Delgado-Vega AM, Martinez-Bueno M, Magro-Checa C, Fernandez C, Castro RO, et al. (2015): PXK locus in systemic lupus erythematosus: Fine mapping and functional analysis reveals novel susceptibility gene ABHD6. Ann Rheum Dis 74:e14.
81. Blankman JL, Long JZ, Trauger SA, Siuzdak G, Cravatt BF (2013): ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC. Proc Natl Acad Sci U S A 110:1500-1505.
82. Fiskerstrand T, H'Mida-Ben Brahim D, Johansson S, M'Zahem A, Haukanes BI, Drouot N, et al. (2010): Mutations in ABHD12 cause the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism. Am J Hum Genet 87:410-417.
83. Kamat SS, Camara K, Parsons WH, Chen DH, Dix MM, Bird TD, et al. (2015): Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay. Nat Chem Biol 11: 164-171.
84. Kim J, Alger BE (2004): Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat Neurosci 7:697-698.
85. Straiker A, Wager-Miller J, Hu SS, Blankman JL, Cravatt BF, Mackie K (2011): COX-2 and fatty acid amide hydrolase can regulate the time course of depolarization-induced suppression of excitation. Br J Pharmacol 164:1672-1683.
86. Sang N, Zhang J, Chen C (2006): PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. J Physiol 572:735-745.
87. Yang H, Zhang J, Andreasson K, Chen C (2008): COX-2 oxidative metabolism of endocannabinoids augments hippocampal synaptic plasticity. Mol Cell Neurosci 37:682-695.
88. Hu SS, Bradshaw HB, Chen JS, Tan B, Walker JM (2008): Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity. Br J Pharmacol 153:1538-1549.
89. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009): Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89:309-380.
90. Pitler TA, Alger BE (1992): Postsynaptic spike firing reduces synaptic GABAA responses in hippocampal pyramidal cells. J Neurosci 12: 4122-4132.
91. Vincent P, Armstrong CM, Marty A (1992): Inhibitory synaptic currents in rat cerebellar Purkinje cells: Modulation by postsynaptic depolarization. J Physiol 456:453-471.
92. Kreitzer AC, Regehr WG (2001): Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29:717-727.
93. Ohno-Shosaku T, Maejima T, Kano M (2001): Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29:729-738.
94. Wilson RI, Nicoll RA (2001): Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410:588-592.
95. Ohno-Shosaku T, Tsubokawa H, Mizushima I, Yoneda N, Zimmer A, Kano M (2002): Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J Neurosci 22:3864-3872.
96. Alger BE (2012): Endocannabinoids at the synapse a decade after the dies mirabilis (29 March 2001): What we still do not know. J Physiol 590:2203-2212.
97. Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y (2012): Endocannabinoid signaling and synaptic function. Neuron 76:70-81.
98. Hentges ST, Low MJ, Williams JT (2005): Differential regulation of synaptic inputs by constitutively released endocannabinoids and exogenous cannabinoids. J Neurosci 25:9746-9751.
99. Neu A, Foldy C, Soltesz I (2007): Postsynaptic origin of CB1- dependent tonic inhibition of GABA release at cholecystokininpositive basket cell to pyramidal cell synapses in the CA1 region of the rat hippocampus. J Physiol 578:233-247.
100. Beinfeld MC, Connolly K (2001): Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids. Neurosci Lett 301:69-71.
101. Taylor SJ, Chae HZ, Rhee SG, Exton JH (1991): Activation of the beta 1 isozyme of phospholipase C by alpha subunits of the Gq class of G proteins. Nature 350:516-518.
102. Bender VA, Bender KJ, Brasier DJ, Feldman DE (2006): Two coincidence detectors for spike timing-dependent plasticity in somatosensory cortex. J Neurosci 26:4166-4177.
103. Hashimotodani Y, Ohno-Shosaku T, Tsubokawa H, Ogata H, Emoto K, Maejima T, et al. (2005): Phospholipase Cbeta serves as a coincidence detector through its Ca21 dependency for triggering retrograde endocannabinoid signal. Neuron 45:257-268.
104. Gerdeman GL, Ronesi J, Lovinger DM (2002): Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 5:446-451.
105. Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ (2002): Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci U S A 99:8384-8388.
106. Chevaleyre V, Castillo PE (2003): Heterosynaptic LTD of hippocampal GABAergic synapses: A novel role of endocannabinoids in regulating excitability. Neuron 38:461-472.
107. Chevaleyre V, Heifets BD, Kaeser PS, Sudhof TC, Castillo PE (2007): Endocannabinoid-mediated long-term plasticity requires cAMP/PKA signaling and RIM1alpha. Neuron 54:801-812.
108. Tsetsenis T, Younts TJ, Chiu CQ, Kaeser PS, Castillo PE, Sudhof TC (2011): Rab3B protein is required for long-term depression of hippocampal inhibitory synapses and for normal reversal learning. Proc Natl Acad Sci U S A 108:14300-14305.
109. Chevaleyre V, Castillo PE (2004): Endocannabinoid-mediated metaplasticity in the hippocampus. Neuron 43:871-881.
110. Jiang B, Huang S, de Pasquale R, Millman D, Song L, Lee HK, et al. (2010): The maturation of GABAergic transmission in visual cortex requires endocannabinoid-mediated LTD of inhibitory inputs during a critical period. Neuron 66:248-259.
111. Kellogg R, Mackie K, Straiker A (2009): Cannabinoid CB1 receptordependent long-term depression in autaptic excitatory neurons. J Neurophysiol 102:1160-1171.
112. Chavez AE, Chiu CQ, Castillo PE (2010): TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus. Nat Neurosci 13:1511-1518.
113. Bacci A, Huguenard JR, Prince DA (2004): Long-lasting self-inhibition of neocortical interneurons mediated by endocannabinoids. Nature 431:312-316.
114. Kreitzer AC, Carter AG, Regehr WG (2002): Inhibition of interneuron firing extends the spread of endocannabinoid signaling in the cerebellum. Neuron 34:787-796.
115. Marinelli S, Pacioni S, Cannich A, Marsicano G, Bacci A (2009): Selfmodulation of neocortical pyramidal neurons by endocannabinoids. Nat Neurosci 12:1488-1490.
116. Marinelli S, Pacioni S, Bisogno T, Di Marzo V, Prince DA, Huguenard JR, et al. (2008): The endocannabinoid 2-arachidonoylglycerol is responsible for the slow self-inhibition in neocortical interneurons. J Neurosci 28:13532-13541.
117. Kenakin T (2002): Efficacy at G-protein-coupled receptors. Nat Rev Drug Discov 1:103-110.
118. Kelley BG, Thayer SA (2004): Delta 9-tetrahydrocannabinol antagonizes endocannabinoid modulation of synaptic transmission between hippocampal neurons in culture. Neuropharmacology 46:709-715.
119. Straiker A, Mackie K (2005): Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J Physiol 569: 501-517.
120. Laaris N, Good CH, Lupica CR (2010): Delta9-tetrahydrocannabinol is a full agonist at CB1 receptors on GABA neuron axon terminals in the hippocampus. Neuropharmacology 59:121-127.
121. Vallee M, Vitiello S, Bellocchio L, Hebert-Chatelain E, Monlezun S, Martin-Garcia E, et al. (2014): Pregnenolone can protect the brain from cannabis intoxication. Science 343:94-98.
122. Huestis MA, Boyd SJ, Heishman SJ, Preston KL, Bonnet D, Le Fur G, et al. (2007): Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) 194:505-515.
123. Evans JM, Hogg MI, Lunn JN, Rosen M (1974): Degree and duration of reversal by naloxone of effects of morphine in conscious subjects. Br Med J. 2:589-591.
124. Gorelick DA, Goodwin RS, Schwilke E, Schwope DM, Darwin WD, Kelly DL, et al. (2011): Antagonist-elicited cannabis withdrawal in humans. J Clin Psychopharmacol 31:603-612.
125. Tsou K, Patrick SL, Walker JM (1995): Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 280:R13-R15.
126. Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, et al. (2009): The acute effects of synthetic intravenous Delta9- tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 39:1607-1616.
127. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. (2004): The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology 29: 1558-1572.
128. Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, et al. (2014): Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 40: 1509-1517.
129. Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, et al. (2009): High-potency cannabis and the risk of psychosis. Br J Psychiatry 195:488-491.
130. van Amsterdam J, Brunt T, van den Brink W (2015): The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol 29:254-263.
131. Blankman JL, Cravatt BF (2013): Chemical probes of endocannabinoid metabolism. Pharmacol Rev 65:849-871.
132. Ueda N, Tsuboi K, Uyama T (2010): N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). Prog Lipid Res 49:299-315.
133. Rouzer CA, Marnett LJ (2011): Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: Cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev 111:5899-5921.